ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Dec 02, 2019 16:57 JST
S&P Global Ratings raises Huatai Securities & Huatai International Outlook to Positive
HONG KONG, Dec 02, 2019 - (ACN Newswire) - S&P Global Ratings last week (November 29, 2019) released a report revising its outlook on the long-term ratings on Huatai Securities Co. Ltd. (Stock Code: 6886.HK; "The Company") and its core subsidiary, Huatai International Financial Holdings Co. Ltd. (HTIF), to positive from stable, while also affirming the Company's 'BBB' long-term issuer credit ratings on both companies. S&P Global Ratings expects the Company to maintain its leading position in most of its businesses for the next 24 months as the company exhibits sound risk management as well as a strengthening capitalization.
"The outlook revision reflects our view that Huatai Securities' capital raising actions and new investment trading plan could enhance its capitalization sustainably." said the report. This statement rings true, as the Company's internationalization has greatly accelerated since the beginning of this year. In June 2019, the Company issued the first ever global depository receipt (GDR) under the London-Shanghai stock connect program to successfully list on the London Stock Exchange. Through the listing, the Company's net assets increased to RMB 116.82 billion, which further enhanced its foothold, visibility and participation in the global capital market. In July 2019, AssetMark, the turnkey asset management platform (TAMP) acquired by the Company in 2016, was successfully listed on the New York Stock Exchange, further strengthening the Company's capitalization and paving way for new international development.
This revised rating will help promote Huatai Securities' position within the global capital market, further reduce the cost of overseas financing, and create beneficial conditions for cross-border business. S&P Global Ratings also noted that the Company's rating could be further upgraded if the risk-adjusted capital (RAC) ratio could be sustainably above 15%. (As of June 30, 2019, the company's RAC ratio was 17.2%.)
Sectors: Daily Finance, Daily News
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Unmanned Aerial Vehicles Being Developed by MHI Used in Demonstration of Automated Transport and Unloading of Heavy Cargo in Disaster Areas
Mar 05, 2025 16:11 JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 05, 2025 09:09 JST
MHI-MS Completes Domestic Development of Vehicle Transport Robot
Mar 04, 2025 19:39 JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 04, 2025 17:22 JST
Prideone Entertainment announces concept for post-war film to mark 80th anniversary of the end of World War II
Mar 04, 2025 16:00 JST
NTT and DOCOMO Successfully Demonstrates On-Demand Unified Control of Computing Services Through Network and Service Integration
Mar 03, 2025 20:25 JST
Space Compass and NTT DOCOMO Successfully Demonstrate Data Connectivity to 4G Devices via HAPS at 20 km Above Kenya
Mar 03, 2025 20:14 JST
TOPPAN and DOCOMO Agree to Innovate Next-Generation 6G Services Using FEEL TECH Communication Technology
Mar 03, 2025 18:32 JST
Rakuten Mobile Partners with Fujitsu to Accelerate 5G Network Expansion
Mar 03, 2025 18:23 JST
Fujitsu unveils 1FINITY 800G ZR/ZR+ coherent pluggable transceivers
Mar 03, 2025 17:58 JST
NEC develops and commercializes 5G-compatible virtualized base stations (vRAN)
Mar 03, 2025 17:42 JST
MHI-MS Delivers Merging Support Information System for Autonomous Truck Trial Project by MLIT
Mar 03, 2025 16:09 JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
Mar 03, 2025 15:41 JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Mar 03, 2025 13:53 JST
Fujitsu's Oyama plant achieves top CSR score for sustainability in global telecom audit
Feb 28, 2025 16:57 JST
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
Feb 28, 2025 12:31 JST
NEC introduces solution to enhance the security of Open vRAN
Feb 28, 2025 11:30 JST
Mazda Production and Sales Results for January 2025
Feb 27, 2025 18:20 JST
Toyota Submits Second Progress Report on Measures to Prevent Recurrence
Feb 27, 2025 18:00 JST
Mazda Conducts Demonstration Operation of Cupola Melting Furnace using Biomass Fuel 100%
Feb 27, 2025 16:27 JST
More Latest Release >>